Radiopharm Theranostics (ASX:RAD) announced financial results for the quarter ended 30 September 2022.
Pivalate achieves positive Phase 2a data in brain mets trial.
Joint venture with MD Anderson to develop novel pharmaceuticals.
FDA grants orphan drug status and rare pediatric disease designation for DUNP19treatment for osteosarcoma.
Entitlement offer raising $10m.
Strategic agreements with Lantheus and NanoMab.
GenesisCare agreements extended to prostate cancer trial.
Clinical supply agreement announced with SHINE Technologies.
Following the announcement the company?s share price fell 8.333%.